120 (939 12)
Pazopanib Tablet, Film Coated
Product Images NDC 42291-939
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Pazopanib (NDC 42291-939). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
New (Pazopanib Tablets 200 mg A217517 1)
1 (Pazopanib Tablets 200 mg A217517 2)
22 (Pazopanib Tablets 200 mg A217517 3)
This data indicates the results of a study comparing the progression-free survival of patients treated with Pazopanib versus a placebo. The median progression-free survival was 4.6 months for Pazopanib (N=246) compared to 1.6 months for the placebo group (N=123). The hazard ratio was calculated as 0.35 with a 95% confidence interval from 0.26 to 0.48, and the p-value was less than 0.001. This suggests that patients treated with Pazopanib had a significantly longer progression-free survival compared to those on placebo.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
